|
|
 |
|
Viewing report
|
|
|
|
U.S. Diabetes Drug Delivery - Physician Perspective
Frost & Sullivan, May 2010, Pages: 47
This study encompasses feedback provided by U.S. physicians who treat diabetes on aspects of drug delivery and drug treatment for diabetes, enabling interested stakeholders to gain insight into current and future trends. Analysis includes issues such as awareness, usage, preferences, influencing criteria, patient compliance, desired delivery types to be made available, as well as feedback on the role the device plays in the prescribing decision for a drug. The corresponding patient deliverable is titled: 2008 U.S. Diabetes Drug Delivery: Patient Perspective (N7C0).
Solution/Outcome
For the full project, all major drug delivery technology categories were assessed. Data was presented for the general objective point questions as well as analysis by disease area. In addition, patient feedback about awareness, usage and desired changes was obtained for Exubera, Byetta, Enbrel, Humira, and Voltaren Gel. Also, for device driven delivery - autoinjector technology usage and willingness for adoption is assessed by patients, as well as other vital feedback on the role the device plays in the overall drug product for both physicians and patients. Proprietary work was analyzed and presented for the partner client assessing physician prescribing behavior and preferences specific to their needs through added proprietary questions in the questionnaire.
The data and information from this project, first made available in January 2008, has now been reanalyzed in full by major disease category, recut and made available as shorter deliverables by disease and respondent type (physician, patient) for our subscription clients.
Research Background – 2010 Analysis
- The physician information in this deliverable is from doctors who stated they actively treat and prescribe for diabetes, with questions framed for them to consider responses within the context of the treatment of diabetes.
- Questions posed to physicians are at the bottom of each analysis slide.
- The corresponding patient deliverable is titled: '2008 U.S. Diabetes Drug Delivery: Patient Perspective' (N7C0).
The study utilized Frost & Sullivan’s web-based capability. A structured questionnaire with the appropriate metrics was set-up in web format (GMI-MR software). Appropriate screening questions and quota controls were provided to ensure that only qualified respondents participate in the survey.
Sample
Over xxx U.S. doctors who treat diabetes participated in the survey. The structure of the sample is shown to the right. Diabetes prescribing for the specialist types has been verified using Wolters Kluwer prescription data.
Reporting Notes
Data resulting from sample sizes less than 50, should be considered directional, not actionable. Some charts may not add to 100.0% due to rounding.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
2008 U.S. Inflammatory Diseases Drug Delivery: Physician Perspective
U.S. Inflammatory Diseases Drug Delivery: Physician Perspective
2008 U.S. Drug Delivery: Neurological Disorders - Physician Perspective
2008 U.S. Diabetes Drug Delivery - Patient Perspective
2008 U.S. Chronic Pain Drug Delivery: Patient Perspective
U.S. Inflammatory Disease Drug Delivery - Patient Perspective
2010 U.S. Type 2 Diabetes Patients’ Choice: Awareness, Usage, and Preferences of Insulin Injection Pens
World Insulin Management Systems Market
India Diabetes Industry Research and Forecasts to FY'2016 - Shift towards Modern Insulin Delivery Devices
Turn of The Decade: Novel Glp-1’s To Emerge as the New Leader in Diabetes Class
|
|
|
|
